Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Ieiri, I' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 25 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ito, S; Ieiri, I; Tanabe, M; Suzuki, A; Higuchi, S; Otsubo, K
      Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

      PHARMACOGENETICS
    2. Hadama, A; Ieiri, I; Morita, T; Kimura, M; Urae, A; Irie, S; Kaneda, T; Mamiya, K; Tashiro, N; Higuchi, S; Otsubo, K
      P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism

      THERAPEUTIC DRUG MONITORING
    3. Mamiya, K; Kojima, K; Yukawa, E; Higuchi, S; Ieiri, I; Ninomiya, H; Tashiro, N
      Phenytoin intoxication induced by fluvoxamine

      THERAPEUTIC DRUG MONITORING
    4. Ieiri, I; Kishimoto, Y; Okochi, H; Momiyama, K; Morita, T; Kitano, M; Morisawa, T; Fukushima, Y; Nakagawa, K; Hasegawa, J; Otsubo, K; Ishizaki, T
      Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    5. Tanabe, M; Ieiri, I; Nagata, N; Inoue, K; Ito, S; Kanamori, Y; Takahashi, M; Kurata, Y; Kigawa, J; Higuchi, S; Terakawa, N; Otsubo, K
      Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    6. Shintani, M; Ieiri, I; Inoue, K; Mamiya, K; Ninomiya, H; Tashiro, N; Higuchi, S; Otsubo, K
      Genetic polymorphisms and functional characterization of the 5 '-flanking region of the human CYP2C9 gene: In vitro and in vivo studies

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    7. Imai, J; Ieiri, I; Mamiya, K; Miyahara, S; Furuumi, H; Nanba, E; Yamane, M; Fukumaki, Y; Ninomiya, H; Tashiro, N; Otsubo, K; Higuchi, S
      Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

      PHARMACOGENETICS
    8. Ieiri, I; Tainaka, H; Morita, T; Hadama, A; Mamiya, K; Hayashibara, M; Ninomiya, H; Ohmori, S; Kitada, M; Tashiro, N; Higuchi, S; Otsubo, K
      Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

      THERAPEUTIC DRUG MONITORING
    9. Ninomiya, H; Mamiya, K; Matsuo, S; Ieiri, I; Higuchi, S; Tashiro, N
      Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication

      THERAPEUTIC DRUG MONITORING
    10. Shimamoto, J; Ieiri, I; Urae, A; Kimura, M; Irie, S; Kubota, T; Chiba, K; Ishizaki, T; Otsubo, K; Higuchi, S
      Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    11. Mamiya, K; Hadama, A; Yukawa, E; Ieiri, I; Otsubo, K; Ninomiya, H; Tashiro, N; Higuchi, S
      CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    12. Kimura, M; Ieiri, I; Wada, Y; Mamiya, K; Urae, A; Iimori, E; Sakai, T; Otsubo, K; Higuchi, S
      Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping:possible effect of age, liver disease and length of therapy

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. MAMIYA K; IEIRI I; MIYAHARA S; IMAI J; FURUUMI H; FUKUMAKI Y; NINOMIYA H; TASHIRO N; YAMADA H; HIGUCHI S
      ASSOCIATION OF POLYMORPHISMS IN THE CYTOCHROME-P450 (CYP) 2C19 AND 2C18 GENES IN JAPANESE EPILEPTIC PATIENTS

      Pharmacogenetics
    14. KIMURA M; IEIRI I; MAMIYA K; URAE F; HIGUCHI S
      GENETIC-POLYMORPHISM OF CYTOCHROME P450S, CYP2C19, AND CYP2C9 IN A JAPANESE POPULATION

      Therapeutic drug monitoring
    15. Mamiya, K; Ieiri, I; Shimamoto, J; Yukawa, E; Imai, J; Ninomiya, H; Yamada, H; Otsubo, K; Higuchi, S; Tashiro, N
      The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics

      EPILEPSIA
    16. IEIRI I; MAMIYA K; URAE A; WADA Y; KIMURA M; IRIE S; AMAMOTO T; KUBOTA T; YOSHIOKA S; NAKAMURA K; NAKANO S; TASHIRO N; HIGUCHI S
      STEREOSELECTIVE 4'-HYDROXYLATION OF PHENYTOIN - RELATIONSHIP TO (S)-MEPHENYTOIN POLYMORPHISM IN JAPANESE

      British journal of clinical pharmacology
    17. IEIRI I; NAKAYAMA J; MURAKAMI H; HORI Y; HIGUCHI S
      EVALUATION OF THE THERAPEUTIC RANGE OF WHOLE-BLOOD CYCLOSPORINE CONCENTRATION IN THE TREATMENT OF PSORIASIS

      International journal of clinical pharmacology and therapeutics
    18. MORISHIGE H; SHUTO H; IEIRI I; OTSUBO K; OISHI R
      INSTABILITY OF STANDARD CALIBRATORS MAY BE INVOLVED IN OVERESTIMATINGVANCOMYCIN CONCENTRATIONS DETERMINED BY FLUORESCENCE POLARIZATION IMMUNOASSAY

      Therapeutic drug monitoring
    19. IEIRI I; MORIOKA T; KIM S; NISHIO S; FUKUI M; HIGUCHI S
      PHARMACOKINETIC STUDY OF ZONISAMIDE IN PATIENTS UNDERGOING BRAIN SURGERY

      Journal of Pharmacy and Pharmacology
    20. IEIRI I; KUBOTA T; URAE A; KIMURA M; WADA Y; MAMIYA K; YOSHIOKA S; IRIE S; AMAMOTO T; NAKAMURA K; NAKANO S; HIGUCHI S
      PHARMACOKINETICS OF OMEPRAZOLE (A SUBSTRATE OF CYP2C19) AND COMPARISON WITH 2 MUTANT ALLELES, C-UPSILON-P2C19(M1) IN EXON-5 AND C-UPSILON-P2C19(M2) IN EXON-4, IN JAPANESE SUBJECTS

      Clinical pharmacology and therapeutics
    21. IEIRI I; GOTO W; HIRATA K; TOSHITANI A; IMAYAMA S; OHYAMA Y; YAMADA H; OHTSUBO K; HIGUCHI S
      THE EFFECT OF 5-(P-HYDROXYPHENYL)-5-PHENYLHYDANTOIN (P-HPPH) ENANTIOMERS, MAJOR METABOLITES OF PHENYTOIN, ON THE OCCURRENCE OF CHRONIC SIDE-EFFECTS - IN-VIVO AND IN-VITRO STUDIES

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    22. TASAKI K; MINAMI T; IEIRI I; OHTSUBO K; HIRAKAWA Y; UEDA K; HIGUCHI S
      DRUG-INTERACTIONS OF ZONISAMIDE WITH PHENYTOIN AND SODIUM VALPROATE -SERUM CONCENTRATIONS AND PROTEIN-BINDING

      Brain & development
    23. IEIRI I; MORIOKA T; ICHIMIYA T; NISHIO S; FUKUI M; OHTSUBO K; HIGUCHI S
      PHARMACOKINETIC STUDY OF VALPROIC ACID SUSTAINED-RELEASE PREPARATION IN PATIENTS UNDERGOING BRAIN SURGERY

      Therapeutic drug monitoring
    24. IEIRI I; GOTO W; HIRATA K; TOSHITANI A; IMAYAMA S; OHYAMA Y; YAMADA H; OHTSUBO K; HIGUCHI S
      EFFECT OF 5-(P HYDROXYPHENYL)-5-PHENYLHYDANTOIN (P-HPPH) ENANTIOMERS,MAJOR METABOLITES OF PHENYTOIN, ON THE OCCURRENCE OF CHRONIC-GINGIVALHYPERPLASIA - IN-VIVO AND IN-VITRO STUDY

      European Journal of Clinical Pharmacology
    25. OHTSUBO K; HIRAKAWA Y; UEDA K; MINAMI T; IEIRI I; HIGUCHI S; AOYAMA T
      INFLUENCE OF ADDITIONAL THERAPY WITH ZONISAMIDE (EXCEGRAN) ON PROTEIN-BINDING AND METABOLISM OF CARBAMAZEPINE

      Epilepsia


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/10/20 alle ore 22:34:35